| Title | Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. | | Author(s) | Jeganathan VS, Verma N | | Institution | aCentre for Eye Research Australia, University of Melbourne, Victoria, Australia bSingapore Eye Research Institute, Singapore National Eye Centre, Singapore cDepartment of Ophthalmology, Royal Hobart Hospital, Australia dHobart Eye Surgeons, Hobart, Tasmania, Australia. | | Source | Curr Opin Ophthalmol 2009 Apr 13. | | Abstract | PURPOSE OF REVIEW: To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD).
RECENT FINDINGS: Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic complications.
SUMMARY: Review of current literature suggests that intravitreal antivascular endothelial growth factor agents are generally a safe and effective treatment for neovascular AMD for up to 2-3 years. Presently, there is level I evidence to substantiate this conclusion for pegaptanib and ranibizumab, but not bevacizumab. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19367163 |
|
